Prospective Study of 18F-RGD PET-CT in Assessment of Response to Antiangiogenic Treatment in Patients With Cancer and Comparison With Perfusion CT
Interventional
Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Changes in tumour uptake (% change in SUVmax) of the fluciclatide imaging agent
Prior to starting anti-angiogenic treatment, repeat after ~4 and 16 weeks of treatment
No
Fergus Gleeson
Principal Investigator
Oxford University Hospitals NHS Trust
United Kingdom: Research Ethics Committee
EP-TSC-663
NCT01492192
April 2013
February 2017
Name | Location |
---|